Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Apr 15;99(8):1888–1896. doi: 10.1172/JCI119356

Autoimmunity caused by disruption of central T cell tolerance. A murine model of drug-induced lupus.

A Kretz-Rommel 1, S R Duncan 1, R L Rubin 1
PMCID: PMC508013  PMID: 9109433

Abstract

A side effect of therapy with procainamide and numerous other medications is a lupus-like syndrome characterized by autoantibodies directed against denatured DNA and the (H2A-H2B)-DNA subunit of chromatin. We tested the possibility that an effect of lupus-inducing drugs on central T cell tolerance underlies these phenomena. Two intrathymic injections of procainamide-hydroxylamine (PAHA), a reactive metabolite of procainamide, resulted in prompt production of IgM antidenatured DNA antibodies in C57BL/6xDBA/2 F1 mice. Subsequently, IgG antichromatin antibodies began to appear in the serum 3 wk after the second injection and were sustained for several months. Specificity, inhibition and blocking studies demonstrated that the PAHA-induced antibodies showed remarkable specificity to the (H2A-H2B)-DNA complex. No evidence for polyclonal B cell activation could be detected based on enumeration of Ig-secreting B cells and serum Ig levels, suggesting that a clonally restricted autoimmune response was induced by intrathymic PAHA. The IgG isotype of the antichromatin antibodies indicated involvement of T cell help, and proliferative responses of splenocytes to oligonucleosomes increased up to 100-fold. As little as 5 microM PAHA led to a 10-fold T cell proliferative response to chromatin in short term organ culture of neonatal thymi. We suggest that PAHA interferes with self-tolerance mechanisms accompanying T cell maturation in the thymus, resulting in the emergence of chromatin-reactive T cells followed by humoral autoimmunity.

Full Text

The Full Text of this article is available as a PDF (232.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams L. E., Balakrishnan K., Roberts S. M., Belcher R., Mongey A. B., Thomas T. J., Hess E. V. Genetic, immunologic and biotransformation studies of patients on procainamide. Lupus. 1993 Apr;2(2):89–98. doi: 10.1177/096120339300200205. [DOI] [PubMed] [Google Scholar]
  2. Adams L. E., Roberts S. M., Donovan-Brand R., Zimmer H., Hess E. V. Study of procainamide hapten-specific antibodies in rabbits and humans. Int J Immunopharmacol. 1993 Nov;15(8):887–897. doi: 10.1016/0192-0561(93)90006-k. [DOI] [PubMed] [Google Scholar]
  3. Adams L. E., Sanders C. E., Jr, Budinsky R. A., Donovan-Brand R., Roberts S. M., Hess E. V. Immunomodulatory effects of procainamide metabolites: their implications in drug-related lupus. J Lab Clin Med. 1989 Apr;113(4):482–492. [PubMed] [Google Scholar]
  4. Amoura Z., Chabre H., Koutouzov S., Lotton C., Cabrespines A., Bach J. F., Jacob L. Nucleosome-restricted antibodies are detected before anti-dsDNA and/or antihistone antibodies in serum of MRL-Mp lpr/lpr and +/+ mice, and are present in kidney eluates of lupus mice with proteinuria. Arthritis Rheum. 1994 Nov;37(11):1684–1688. doi: 10.1002/art.1780371118. [DOI] [PubMed] [Google Scholar]
  5. Ashton-Rickardt P. G., Tonegawa S. A differential-avidity model for T-cell selection. Immunol Today. 1994 Aug;15(8):362–366. doi: 10.1016/0167-5699(94)90174-0. [DOI] [PubMed] [Google Scholar]
  6. Bell S. A., Hobbs M. V., Rubin R. L. Isotype-restricted hyperimmunity in a murine model of the toxic oil syndrome. J Immunol. 1992 Jun 1;148(11):3369–3376. [PubMed] [Google Scholar]
  7. Bevan M. J., Hogquist K. A., Jameson S. C. Selecting the T cell receptor repertoire. Science. 1994 May 6;264(5160):796–797. doi: 10.1126/science.8171333. [DOI] [PubMed] [Google Scholar]
  8. Blackman M. A., Burgert H. G., Gerhard-Burgert H., Woodland D. L., Palmer E., Kappler J. W., Marrack P. A role for clonal inactivation in T cell tolerance to Mls-1a. Nature. 1990 Jun 7;345(6275):540–542. doi: 10.1038/345540a0. [DOI] [PubMed] [Google Scholar]
  9. Burlingame R. W., Boey M. L., Starkebaum G., Rubin R. L. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest. 1994 Jul;94(1):184–192. doi: 10.1172/JCI117305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Burlingame R. W., Rubin R. L., Balderas R. S., Theofilopoulos A. N. Genesis and evolution of antichromatin autoantibodies in murine lupus implicates T-dependent immunization with self antigen. J Clin Invest. 1993 Apr;91(4):1687–1696. doi: 10.1172/JCI116378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Burlingame R. W., Rubin R. L. Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin. J Clin Invest. 1991 Aug;88(2):680–690. doi: 10.1172/JCI115353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Burlingame R. W., Rubin R. L. Subnucleosome structures as substrates in enzyme-linked immunosorbent assays. J Immunol Methods. 1990 Dec 5;134(2):187–199. doi: 10.1016/0022-1759(90)90380-e. [DOI] [PubMed] [Google Scholar]
  13. Chabre H., Amoura Z., Piette J. C., Godeau P., Bach J. F., Koutouzov S. Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. Arthritis Rheum. 1995 Oct;38(10):1485–1491. doi: 10.1002/art.1780381015. [DOI] [PubMed] [Google Scholar]
  14. Dayal A. K., Kammer G. M. The T cell enigma in lupus. Arthritis Rheum. 1996 Jan;39(1):23–33. doi: 10.1002/art.1780390104. [DOI] [PubMed] [Google Scholar]
  15. Desai-Mehta A., Mao C., Rajagopalan S., Robinson T., Datta S. K. Structure and specificity of T cell receptors expressed by potentially pathogenic anti-DNA autoantibody-inducing T cells in human lupus. J Clin Invest. 1995 Feb;95(2):531–541. doi: 10.1172/JCI117695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Duncan S. R., Rubin R. L., Burlingame R. W., Sinclair S. B., Pekny K. W., Theofilopoulos A. N. Intrathymic injection of polynucleosomes delays autoantibody production in BXSB mice. Clin Immunol Immunopathol. 1996 May;79(2):171–181. doi: 10.1006/clin.1996.0064. [DOI] [PubMed] [Google Scholar]
  17. Giardina E. G., Heissenbuttel R. H., Bigger J. T., Jr Intermittent intravenous procaine amide to treat ventricular arrhythmias. Correlation of plasma concentration with effect on arrhythmia, electrocardiogram, and blood pressure. Ann Intern Med. 1973 Feb;78(2):183–193. doi: 10.7326/0003-4819-78-2-183. [DOI] [PubMed] [Google Scholar]
  18. Gleichmann E., Van Elven E. H., Van der Veen J. P. A systemic lupus erythematosus (SLE)-like disease in mice induced by abnormal T-B cell cooperation. Preferential formation of autoantibodies characteristic of SLE. Eur J Immunol. 1982 Feb;12(2):152–159. doi: 10.1002/eji.1830120210. [DOI] [PubMed] [Google Scholar]
  19. Godfrey J. E., Baxevanis A. D., Moudrianakis E. N. Spectropolarimetric analysis of the core histone octamer and its subunits. Biochemistry. 1990 Jan 30;29(4):965–972. doi: 10.1021/bi00456a018. [DOI] [PubMed] [Google Scholar]
  20. González-Quintial R., Theofilopoulos A. N. V beta gene repertoires in aging mice. J Immunol. 1992 Jul 1;149(1):230–236. [PubMed] [Google Scholar]
  21. Hill C. M., Lunec J., Griffiths H. R., Herbert K. E. Characterization of tumour necrosis factor alpha release by human granulocytes in response to procainamide challenge. Biochem Pharmacol. 1995 Jun 16;49(12):1837–1849. doi: 10.1016/0006-2952(94)00523-o. [DOI] [PubMed] [Google Scholar]
  22. Hogquist K. A., Jameson S. C., Heath W. R., Howard J. L., Bevan M. J., Carbone F. R. T cell receptor antagonist peptides induce positive selection. Cell. 1994 Jan 14;76(1):17–27. doi: 10.1016/0092-8674(94)90169-4. [DOI] [PubMed] [Google Scholar]
  23. Jameson S. C., Hogquist K. A., Bevan M. J. Positive selection of thymocytes. Annu Rev Immunol. 1995;13:93–126. doi: 10.1146/annurev.iy.13.040195.000521. [DOI] [PubMed] [Google Scholar]
  24. Jenkins M. K., Schwartz R. H., Pardoll D. M. Effects of cyclosporine A on T cell development and clonal deletion. Science. 1988 Sep 23;241(4873):1655–1658. doi: 10.1126/science.241.4873.1655. [DOI] [PubMed] [Google Scholar]
  25. Jiang X., Khursigara G., Rubin R. L. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science. 1994 Nov 4;266(5186):810–813. doi: 10.1126/science.7973636. [DOI] [PubMed] [Google Scholar]
  26. Kawai K., Ohashi P. S. Immunological function of a defined T-cell population tolerized to low-affinity self antigens. Nature. 1995 Mar 2;374(6517):68–69. doi: 10.1038/374068a0. [DOI] [PubMed] [Google Scholar]
  27. Kramers C., Hylkema M. N., van Bruggen M. C., van de Lagemaat R., Dijkman H. B., Assmann K. J., Smeenk R. J., Berden J. H. Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest. 1994 Aug;94(2):568–577. doi: 10.1172/JCI117371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Kubicka-Muranyi M., Goebels R., Goebel C., Uetrecht J., Gleichmann E. T lymphocytes ignore procainamide, but respond to its reactive metabolites in peritoneal cells: demonstration by the adoptive transfer popliteal lymph node assay. Toxicol Appl Pharmacol. 1993 Sep;122(1):88–94. doi: 10.1006/taap.1993.1175. [DOI] [PubMed] [Google Scholar]
  29. Kühn R., Rajewsky K., Müller W. Generation and analysis of interleukin-4 deficient mice. Science. 1991 Nov 1;254(5032):707–710. doi: 10.1126/science.1948049. [DOI] [PubMed] [Google Scholar]
  30. Lefkowith J. B., Gilkeson G. S. Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Arthritis Rheum. 1996 Jun;39(6):894–903. doi: 10.1002/art.1780390605. [DOI] [PubMed] [Google Scholar]
  31. Lefkowith J. B., Kiehl M., Rubenstein J., DiValerio R., Bernstein K., Kahl L., Rubin R. L., Gourley M. Heterogeneity and clinical significance of glomerular-binding antibodies in systemic lupus erythematosus. J Clin Invest. 1996 Sep 15;98(6):1373–1380. doi: 10.1172/JCI118924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Lutter L. C. Kinetic analysis of deoxyribonuclease I cleavages in the nucleosome core: evidence for a DNA superhelix. J Mol Biol. 1978 Sep 15;124(2):391–420. doi: 10.1016/0022-2836(78)90306-6. [DOI] [PubMed] [Google Scholar]
  33. McHeyzer-Williams M. G., Nossal G. J. Clonal analysis of autoantibody-producing cell precursors in the preimmune B cell repertoire. J Immunol. 1988 Dec 15;141(12):4118–4123. [PubMed] [Google Scholar]
  34. Mohan C., Adams S., Stanik V., Datta S. K. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med. 1993 May 1;177(5):1367–1381. doi: 10.1084/jem.177.5.1367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Monestier M., Novick K. E. Specificities and genetic characteristics of nucleosome-reactive antibodies from autoimmune mice. Mol Immunol. 1996 Jan;33(1):89–99. doi: 10.1016/0161-5890(95)00115-8. [DOI] [PubMed] [Google Scholar]
  36. Morris S. C., Cheek R. L., Cohen P. L., Eisenberg R. A. Autoantibodies in chronic graft versus host result from cognate T-B interactions. J Exp Med. 1990 Feb 1;171(2):503–517. doi: 10.1084/jem.171.2.503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Portanova J. P., Arndt R. E., Kotzin B. L. Selective production of autoantibodies in graft-vs-host-induced and spontaneous murine lupus. Predominant reactivity with histone regions accessible in chromatin. J Immunol. 1988 Feb 1;140(3):755–760. [PubMed] [Google Scholar]
  38. Prud'homme G. J., Sanders R., Parfrey N. A., Ste-Croix H. T-cell maturation and clonal deletion in cyclosporine-induced autoimmunity. J Autoimmun. 1991 Apr;4(2):357–368. doi: 10.1016/0896-8411(91)90030-g. [DOI] [PubMed] [Google Scholar]
  39. Quddus J., Johnson K. J., Gavalchin J., Amento E. P., Chrisp C. E., Yung R. L., Richardson B. C. Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J Clin Invest. 1993 Jul;92(1):38–53. doi: 10.1172/JCI116576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Ramsdell F., Fowlkes B. J. Clonal deletion versus clonal anergy: the role of the thymus in inducing self tolerance. Science. 1990 Jun 15;248(4961):1342–1348. doi: 10.1126/science.1972593. [DOI] [PubMed] [Google Scholar]
  41. Ramsdell F., Lantz T., Fowlkes B. J. A nondeletional mechanism of thymic self tolerance. Science. 1989 Nov 24;246(4933):1038–1041. doi: 10.1126/science.2511629. [DOI] [PubMed] [Google Scholar]
  42. Roberts J. L., Sharrow S. O., Singer A. Clonal deletion and clonal anergy in the thymus induced by cellular elements with different radiation sensitivities. J Exp Med. 1990 Mar 1;171(3):935–940. doi: 10.1084/jem.171.3.935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Roberts S. M., Adams L. E., Donovan-Brand R., Budinsky R., Skoulis N. P., Zimmer H., Hess E. V. Procainamide hydroxylamine lymphocyte toxicity--I. Evidence for participation by hemoglobin. Int J Immunopharmacol. 1989;11(4):419–427. doi: 10.1016/0192-0561(89)90089-1. [DOI] [PubMed] [Google Scholar]
  44. Rozendaal L., Pals S. T., Gleichmann E., Melief C. J. Persistence of allospecific helper T cells is required for maintaining autoantibody formation in lupus-like graft-versus-host disease. Clin Exp Immunol. 1990 Dec;82(3):527–532. doi: 10.1111/j.1365-2249.1990.tb05484.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Rubin R. L., Bell S. A., Burlingame R. W. Autoantibodies associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA complex. J Clin Invest. 1992 Jul;90(1):165–173. doi: 10.1172/JCI115832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Rubin R. L., Burlingame R. W., Arnott J. E., Totoritis M. C., McNally E. M., Johnson A. D. IgG but not other classes of anti-[(H2A-H2B)-DNA] is an early sign of procainamide-induced lupus. J Immunol. 1995 Mar 1;154(5):2483–2493. [PubMed] [Google Scholar]
  47. Rubin R. L., Curnutte J. T. Metabolism of procainamide to the cytotoxic hydroxylamine by neutrophils activated in vitro. J Clin Invest. 1989 Apr;83(4):1336–1343. doi: 10.1172/JCI114020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Rubin R. L. Role of xenobiotic oxidative metabolism. Lupus. 1994 Dec;3(6):479–482. doi: 10.1177/096120339400300609. [DOI] [PubMed] [Google Scholar]
  49. Rubin R. L., Tang F. L., Tsay G., Pollard K. M. Pseudoautoimmunity in normal mice: anti-histone antibodies elicited by immunization versus induction during graft-versus-host reaction. Clin Immunol Immunopathol. 1990 Feb;54(2):320–332. doi: 10.1016/0090-1229(90)90093-6. [DOI] [PubMed] [Google Scholar]
  50. Rubin R. L., Uetrecht J. P., Jones J. E. Cytotoxicity of oxidative metabolites of procainamide. J Pharmacol Exp Ther. 1987 Sep;242(3):833–841. [PubMed] [Google Scholar]
  51. Sebzda E., Wallace V. A., Mayer J., Yeung R. S., Mak T. W., Ohashi P. S. Positive and negative thymocyte selection induced by different concentrations of a single peptide. Science. 1994 Mar 18;263(5153):1615–1618. doi: 10.1126/science.8128249. [DOI] [PubMed] [Google Scholar]
  52. Sedgwick J. D., Holt P. G. A solid-phase immunoenzymatic technique for the enumeration of specific antibody-secreting cells. J Immunol Methods. 1983 Feb 25;57(1-3):301–309. doi: 10.1016/0022-1759(83)90091-1. [DOI] [PubMed] [Google Scholar]
  53. Self C. H. Enzyme amplification--a general method applied to provide an immunoassisted assay for placental alkaline phosphatase. J Immunol Methods. 1985 Feb 11;76(2):389–393. doi: 10.1016/0022-1759(85)90316-3. [DOI] [PubMed] [Google Scholar]
  54. Stevens T. L., Bossie A., Sanders V. M., Fernandez-Botran R., Coffman R. L., Mosmann T. R., Vitetta E. S. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature. 1988 Jul 21;334(6179):255–258. doi: 10.1038/334255a0. [DOI] [PubMed] [Google Scholar]
  55. Theofilopoulos A. N., Dixon F. J. Murine models of systemic lupus erythematosus. Adv Immunol. 1985;37:269–390. doi: 10.1016/s0065-2776(08)60342-9. [DOI] [PubMed] [Google Scholar]
  56. Uetrecht J. P. Reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide. J Pharmacol Exp Ther. 1985 Feb;232(2):420–425. [PubMed] [Google Scholar]
  57. Uetrecht J. Mechanism of hypersensitivity reactions: proposed involvement of reactive metabolites generated by activated leukocytes. Trends Pharmacol Sci. 1989 Nov;10(11):463–467. doi: 10.1016/S0165-6147(89)80012-4. [DOI] [PubMed] [Google Scholar]
  58. Urdahl K. B., Pardoll D. M., Jenkins M. K. Self-reactive T cells are present in the peripheral lymphoid tissues of cyclosporin A-treated mice. Int Immunol. 1992 Dec;4(12):1341–1349. doi: 10.1093/intimm/4.12.1341. [DOI] [PubMed] [Google Scholar]
  59. Wheeler J. F., Adams L. E., Mongey A. B., Roberts S. M., Heineman W. R., Hess E. V. Determination of metabolically derived nitroprocainamide in the urine of procainamide-dosed humans and rats by liquid chromatography with electrochemical detection. Drug Metab Dispos. 1991 May-Jun;19(3):691–695. [PubMed] [Google Scholar]
  60. Wheeler J. F., Lunte C. E., Heineman W. R., Adams L., Hess E. V. Electrochemical determination of N-oxidized procainamide metabolites and functional assessment of effects on murine cells in vitro. Proc Soc Exp Biol Med. 1988 Jul;188(3):381–386. doi: 10.3181/00379727-188-3-rc1. [DOI] [PubMed] [Google Scholar]
  61. Yung R. L., Richardson B. C. Drug-induced lupus. Rheum Dis Clin North Am. 1994 Feb;20(1):61–86. [PubMed] [Google Scholar]
  62. von Boehmer H. Positive selection of lymphocytes. Cell. 1994 Jan 28;76(2):219–228. doi: 10.1016/0092-8674(94)90330-1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES